Overview / Abstract: |
Patients with frequent migraines and/or who experience functional disability need preventative migraine treatment. However, studies have shown that of the 38% of patients who stand to benefit from prophylactic therapy, only 3-13% of them actually receive it. Calcitonin gene-related peptide (CGRP) monoclonal antibodies are under clinical investigation and constitute a new prophylactic migraine therapy class. Increased physician attention when individualizing treatment plans to maximize therapy efficacy and minimize side effects as well as managing headache triggers and existing comorbidities continue to be vital strategies as new agents emerge and when maximizing patient function. |
Expiration |
Dec 29, 2017 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Webinar / Webcast / Video |
Credits / Hours |
1.00 AMA PRA Category 1 Credit™ |
Accreditation |
ACHL |
Presenters / Authors / Faculty |
Mayo Clinic, Deborah I. Friedman, MD, MPH, FAHS, and |
Sponsors / Supporters / Grant Providers |
Lilly |
Keywords / Search Terms |
ACHL CGRP, chronic migraine, Lilly, CME, chronic, disorder, sensitivity, migraine, chronic Free CE CME |